How much does one dose of Cemiplimab cost, combined with the real market prices in different countries and regions?

Cemiplimab is an anti-PD-1 immune checkpoint inhibitor mainly used to treat patients with locally advanced or metastatic cutaneous squamous cell carcinoma and some non-small cell lung cancer. It is not currently available in the domestic market, so domestic patients cannot obtain the drug directly through hospitals or pharmacies, and it is not included in the medical insurance reimbursement system, resulting in a lack of clear data on domestic price information.

In overseas markets, cimepilimab is already available in the US and European versions of the original drug. The common specifications are 350mg/7mL (50mg/mL). The price per box varies greatly, ranging from RMB 40,000 to RMB 100,000. This price range is mainly affected by exchange rates, regional pricing policies and market supply and demand, and is also related to medical insurance coverage. In the United States, some patients may receive a level of financial assistance through commercial insurance or pharmaceutical assistance programs, thereby reducing actual out-of-pocket costs.

Prices in the European market also vary. Due to different medical insurance reimbursement policies, taxes and hospital procurement mechanisms in different countries, the actual price of each drug may fluctuate. For example, in some Western European countries, after reimbursement through the national medical system, the patient's out-of-pocket payment ratio can be significantly reduced, but in areas not included in the reimbursement system, the price is close to the original listing level. Overall, cimepilimab is a high-priced original drug overseas, and its acquisition cost is relatively high. Patients and doctors need to fully consider affordability.

There are currently no generics or biosimilars of cimepilimab on the market, which means that even if overseas patients want to reduce costs through generic drugs, they are temporarily unable to do so. Therefore, patients who use this drug usually need to purchase the original drug through formal medical channels and combine it with the medical insurance or drug assistance policy of their country to ensure treatment accessibility and affordability. In the future, with the launch of generic drugs and adjustments to medical insurance policies, their prices and accessibility may further improve.

Keyword tags: cimepilimab, price, market, PD-1 inhibitor, cutaneous squamous cell carcinoma, non-small cell lung cancer, overseas drug purchase, original drug, generic drug.

Reference materials:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-libtayo-cemiplimab-rwlc